Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6

Clinical Cancer Research

Volumn 21, Issue 19, 2015, Pages 4431-4439

  Draper, Lindsey M ^a   Kwong, Mei Li M ^a   Gros, Alena ^a   Stevanović, Sanja ^a   Tran, Eric ^a   Kerkar, Sid ^a   Raffeld, Mark ^a   Rosenberg, Steven A ^a   Hinrichs, Christian S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A ANTIGEN; PROTEIN E6; T LYMPHOCYTE RECEPTOR; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; HLA A2 ANTIGEN; HYBRID PROTEIN; ONCOPROTEIN; PROTEIN BINDING; REPRESSOR PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN RECOGNITION; ANUS CANCER; ARTICLE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CELL BASED GENE THERAPY; CELLULAR IMMUNITY; CERVICAL CANCER CELL LINE; CONTROLLED STUDY; CROSS REACTION; EPITHELIAL CANCER CELL LINE; FEMALE; GENE EXPRESSION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; METASTASIS; OROPHARYNX CANCER; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; ANUS NEOPLASMS; CARCINOMA; DENDRITIC CELL; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; T LYMPHOCYTE RECEPTOR GENE; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE; UTERINE CERVICAL NEOPLASMS;

ANUS NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CROSS REACTIONS; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FEMALE; GENE EXPRESSION; GENES, T-CELL RECEPTOR; HLA-A2 ANTIGEN; HUMAN PAPILLOMAVIRUS 16; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASM METASTASIS; ONCOGENE PROTEINS, VIRAL; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS; TRANSDUCTION, GENETIC; UTERINE CERVICAL NEOPLASMS;

EID: 84945585091     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3341     Document Type: Article

References (40)

1. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive Tcell therapy for cancer. Immunol Rev 2014;257:56-71.
2. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17:4550-7.
3. Stevanović S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 2015;33:1543-50.
4. + T cells in a patient with epithelial cancer. Science 2014;344:641-5.
5. Hinrichs CS, Restifo NP. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol 2013;31:999-1008.
6. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan D-AN, Feldman SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2010;19:620-6.
7. Lamers CHJ, Sleijfer S, Vulto AG, Kruit WHJ, Kliffen M, Debets R, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006;24:e20-2.
8. Maciag PC, Radulovic S, Rothman J. The first clinical use of a liveattenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 2009;27:3975-83.
9. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347:1523-7.
10. Steller MA, Gurski KJ, Murakami M, Daniel RW, Shah KV, Celis E, et al. Cellmediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998;4:2103-9.
11. Ferrara A, Nonn M, Sehr P, Schreckenberger C, Pawlita M, Dürst M, et al. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 2003;129: 521-30.
12. Van Poelgeest MIE, Welters MJP, van Esch EMG, Stynenbosch LFM, Kerpershoek G, van Persijn van Meerten EL, et al. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med 2013;11:88.
13. Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2002;2:59-64.
14. Bhat P, Mattarollo SR, Gosmann C, Frazer IH, Leggatt GR. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy. Immunol Rev 2011;239:85-98.
15. Evans M, Borysiewicz LK, Evans AS, Rowe M, Jones M, Gileadi U, et al. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J Immunol 2001;167: 5420-8.
16. Albers A, Abe K, Hunt J, Wang J, Lopez-Albaitero A, Schaefer C, et al. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 2005;65:11146-55.
17. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WGV, Castle PE. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009;101:475-87.
18. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a metaanalysis. Int J Cancer 2009;124:1626-36.
19. + epithelial cancers. J Biol Chem 2010;285:29608-22.
20. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003;26:332-42.
21. + T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 2011; 117:808-14.
22. + T cells responding to antigen without requiring knowledge of epitope specificities. Blood 2007;110: 201-10.
23. Robbins PF, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol 2008;180:6116-31.
24. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NYESO-1. J Clin Oncol 2011;29:917-24.
25. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009;114:535-46.
26. Parkhurst MR, Joo J, Riley JP, Yu Z, Li Y, Robbins PF, et al. Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin Cancer Res Off J Am Assoc Cancer Res 2009;15:169-80.
27. Georgopoulos NT, Proffitt JL, Blair GE. Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins. Oncogene 2000;19:4930-5.
28. Heller C, Weisser T, Mueller-Schickert A, Rufer E, Hoh A, Leonhardt RM, et al. Identification of key amino acid residues that determine the ability of high risk HPV16-E7 to dysregulate major histocompatibility complex class I expression. J Biol Chem 2011;286:10983-97.
29. Dunn LA, Evander M, Tindle RW, Bulloch AL, de Kluyver RL, Fernando GJ, et al. Presentation of the HPV16E7 protein by skin grafts is insufficient to allow graft rejection in an E7-primed animal. Virology 1997;235:94-103.
30. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010;10:550-60.
31. Kenter GG, Welters MJP, Valentijn ARPM, Lowik MJG, Berends-van der Meer DMA, Vloon APG, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009;361:1838-47.
32. Welters MJP, Kenter GG, de Vos van Steenwijk PJ, Löwik MJG, Berendsvan der Meer DMA, Essahsah F, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A 2010;107: 11895-9.
33. Hinrichs CS, Stevanović S, Draper L, Somerville R, Wunderlich J, Restifo NP, et al. HPV-targeted tumor-infiltrating lymphocytes for cervical cancer. J Clin Oncol [Internet] 2014 [cited 2014 Jul 20];32:5s. Available from: http://meetinglibrary.asco.org/content/129263-144
34. De Vos van Steenwijk PJ, Heusinkveld M, Ramwadhdoebe TH, Löwik MJ, van der Hulst JM, Goedemans R, et al. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. Cancer Res 2010;70:2707-17.
35. Piersma SJ, Welters MJP, van der Hulst JM, Kloth JN, Kwappenberg KMC, Trimbos BJ, et al. Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. Int J Cancer 2008;122:486-94.
36. + T cells mediate superior antitumor immunity. Proc Natl Acad Sci 2009;106:17469-74.
37. + T cells display enhanced antitumorimmunity. Blood 2009;114:596-9.
38. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity enhanced T cells in myeloma and melanoma. Blood 2013;122:863-71.
39. Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, et al. Identification of a titin-derived HLA-A1-presented peptide as a crossreactive target for engineered MAGE A3-directed T cells. Sci Transl Med 2013;5:197ra103.
40. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013;36:133-51.